Peter J M Valk

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations
    Saman Abbas
    Haematologica 99:848-57. 2014
  2. pmc A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC
    Jaap Brand
    Skyline Diagnostics BV, Rotterdam Science Tower, Marconistraat 16, 3029 AK, Rotterdam, The Netherlands
    Exp Hematol Oncol 2:7. 2013
  3. pmc Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
    Marta Pratcorona
    Department of Hematology, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
    Haematologica 97:388-92. 2012
  4. doi request reprint Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Treat Res 145:67-83. 2010
  5. ncbi request reprint Prognostically useful gene-expression profiles in acute myeloid leukemia
    Peter J M Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 350:1617-28. 2004
  6. doi request reprint Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia
    Sanne Lugthart
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 28:3890-8. 2010
  7. pmc HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Bioinformatics 7:337. 2006
  8. doi request reprint Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
    Ana Flávia Tibúrcio Ribeiro
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 119:5824-31. 2012
  9. doi request reprint High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
    Sanne Lugthart
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 111:4329-37. 2008
  10. ncbi request reprint Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center Rotterdam, Ee1391a, Dr Molewaterplein 50, 3015 GE Rotterdam Z H, The Netherlands
    Blood 106:3747-54. 2005

Detail Information

Publications55

  1. ncbi request reprint Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations
    Saman Abbas
    Haematologica 99:848-57. 2014
    ..In conclusion, by an integrated approach involving high-throughput genome-wide genotyping and gene expression profiling we identified BCL11B as a candidate oncogene in acute myeloid leukemia. ..
  2. pmc A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC
    Jaap Brand
    Skyline Diagnostics BV, Rotterdam Science Tower, Marconistraat 16, 3029 AK, Rotterdam, The Netherlands
    Exp Hematol Oncol 2:7. 2013
    ..We have developed a highly standardized molecular assay for the independent gene expression markers EVI1 and BAALC...
  3. pmc Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
    Marta Pratcorona
    Department of Hematology, IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Spain
    Haematologica 97:388-92. 2012
    ..52, P=0.032). In conclusion, ASXL1 mutations are common mutations in acute myeloid leukemia and indicate a poor therapy outcome...
  4. doi request reprint Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer Treat Res 145:67-83. 2010
    ..The current advances made in molecular understanding of AML will ultimately lead to a further refinement of prognostics of AML...
  5. ncbi request reprint Prognostically useful gene-expression profiles in acute myeloid leukemia
    Peter J M Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    N Engl J Med 350:1617-28. 2004
    ..However, this combined approach provides correct therapeutic and prognostic information in only 50 percent of cases...
  6. doi request reprint Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia
    Sanne Lugthart
    Erasmus University Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 28:3890-8. 2010
    ..2) [inv(3)/t(3;3)] is recognized as a distinctive entity in the WHO classification. Risk assignment and clinical and genetic characterization of AML with chromosome 3q abnormalities other than inv(3)/t(3;3) remain largely unresolved...
  7. pmc HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Bioinformatics 7:337. 2006
    ..Here, we describe an approach to visually integrate the results of unsupervised and supervised cluster analysis using a correlation plot and additional sample metadata...
  8. doi request reprint Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia
    Ana Flávia Tibúrcio Ribeiro
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 119:5824-31. 2012
    ..We conclude that DNMT3A mutation status is an important factor to consider for risk stratification of patients with AML...
  9. doi request reprint High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
    Sanne Lugthart
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 111:4329-37. 2008
    ..001 and event-free survival [EFS]: P = .002). We argue that EVI1/ME quantitative expression analysis should be implemented in the molecular diagnostic procedures of AML...
  10. ncbi request reprint Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance
    Roel G W Verhaak
    Department of Hematology, Erasmus University Medical Center Rotterdam, Ee1391a, Dr Molewaterplein 50, 3015 GE Rotterdam Z H, The Netherlands
    Blood 106:3747-54. 2005
    ..Finally, in multivariable analysis NPM1 mutations express independent favorable prognostic value with regard to OS, EFS, and disease-free survival (DFS)...
  11. pmc Retroviral integration mutagenesis in mice and comparative analysis in human AML identify reduced PTP4A3 expression as a prognostic indicator
    Renee Beekman
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    PLoS ONE 6:e26537. 2011
    ..In conclusion, our novel strategy has identified PTP4A3 to potentially have a role in AML, on one hand as a candidate HIG contributing to leukemogenesis in mice and on the other hand as a prognostic indicator in human AML...
  12. doi request reprint Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers
    Veronika Rockova
    Departments of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 118:1069-76. 2011
    ..9% vs 14.9%). The integrated statistical approach demonstrates that from the multitude of biomarkers a greatly condensed subset can be selected for improved stratification of intermediate-risk AML...
  13. pmc SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels
    Mathijs A Sanders
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Genomics 9:41. 2008
    ..In fact, obtaining an integrated view of both large scale SNP genotyping and gene expression is currently complicated since only a limited number of appropriate software tools are available...
  14. doi request reprint High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities
    Stefan Gröschel
    Erasmus University Medical Center, Department of Hematology, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Clin Oncol 28:2101-7. 2010
    ..It predicts poor outcome, particularly among intermediate cytogenetic risk AML. Patients with EVI1(+) AML may benefit from allogeneic transplantation in first CR. Pretreatment EVI1 screening should be included in risk stratification...
  15. pmc Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
    Bas J Wouters
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 113:3088-91. 2009
    ..These results demonstrate significant underlying heterogeneity within CEBPA mutation-positive AML with prognostic relevance...
  16. ncbi request reprint Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia
    Stefan J Erkeland
    Department of Hematology, Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands
    Cancer Res 66:622-6. 2006
    ....
  17. doi request reprint High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
    Noortje Thielen
    Department of Hematology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Ann Hematol 92:1049-56. 2013
    ..However, the underpowering of the study precludes any definitive conclusions. This trial is registered at www.trialregister.nl (NTR674). ..
  18. pmc Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
    Roel G W Verhaak
    Erasmus University Medical Center Rotterdam, Department of Hematology, Rotterdam, The Netherlands
    Haematologica 94:131-4. 2009
    ..g. those characterized by expression of chimeric transcription factors. However, detection of mutations affecting signaling molecules and numerical abnormalities still requires alternative molecular methods...
  19. ncbi request reprint Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML
    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
    Institute of Hematology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Hematol J 4:31-40. 2003
    ..By including this newly developed PCR assay, we define a subgroup of good-risk patients within the heterogeneous intermediate-risk group of AML...
  20. pmc Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array
    Martin H van Vliet
    Skyline Diagnostics BV, Rotterdam, The Netherlands
    Genet Test Mol Biomarkers 17:395-400. 2013
    ..In conclusion, gene expression profiling provides a reliable method for CEBPA double-mutation detection in patients with AML for clinical use...
  21. pmc The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia
    Eric van den Akker
    Department of Hematology, Erasmus University Medical Center, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    J Virol 79:5249-58. 2005
    ..These findings suggest that we identified a novel proto-oncogene that may be causally linked to certain types of human leukemia...
  22. doi request reprint Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value
    Saman Abbas
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 116:2122-6. 2010
    ..Thus, IDH1 and IDH2 mutations are common genetic aberrations in AML, and IDH1 mutations may carry prognostic value in distinct subtypes of AML...
  23. pmc Detection of mutant NPM1 mRNA in acute myeloid leukemia using custom gene expression arrays
    Martin H van Vliet
    Skyline Diagnostics BV, Rotterdam, The Netherlands
    Genet Test Mol Biomarkers 17:295-300. 2013
    ..7%). Based on this, we conclude that this method provides a reliable method for NPM1 mutation detection. The method can be applied to other genes/mutations as long as the mutant alleles are sufficiently highly expressed...
  24. doi request reprint NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern
    Iris H I M Hollink
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Blood 118:3645-56. 2011
    ..Taken together, NUP98/NSD1 identifies a previously unrecognized group of young AML patients, with distinct characteristics and dismal prognosis, for whom new treatment strategies are urgently needed...
  25. pmc The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies
    Roel G W Verhaak
    Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
    BMC Bioinformatics 7:105. 2006
    ..By focusing on practical applications of microarray-based research, this study provides insight into the relevance of pre-processing procedures to biology-oriented researchers...
  26. pmc Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia
    Iris H I M Hollink
    Pediatric Oncology Hematology, Erasmus MC Sophia Children s Hospital, Rotterdam, The Netherlands
    Haematologica 96:384-92. 2011
    ..Our objective was to investigate the characteristics, gene expression profiles and prognostic impact of the different CEBPA aberrations in pediatric acute myeloid leukemia...
  27. doi request reprint MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia
    Mojca Jongen-Lavrencic
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 111:5078-85. 2008
    ..MicroRNA expression apparently bears specific relationships to the heterogeneous pathobiology of AML. Distinctive microRNA signatures appear of potential value in the clinical diagnosis of AML...
  28. doi request reprint Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
    Erdogan Taskesen
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 117:2469-75. 2011
    ..Based on these findings, we propose that CEBPA(dm) should be clearly defined from CEBPA(sm) AML and considered as a separate entity in the classification of AML...
  29. doi request reprint Addition of β-mercaptoethanol is a prerequisite for high-quality RNA isolation using QIAsymphony technology as demonstrated by detection of molecular aberrations in hematologic malignancies
    Sonja C P A M van der Poel-van de Luytgaarde
    Department of Hematology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Genet Test Mol Biomarkers 17:475-80. 2013
    ..Moreover, cases of myeloproliferative neoplasms (MPN) with low levels of JAK2 V617F mRNA were even missed in QST when lysis buffer RLT Plus was used, but they were readily detected after addition of BME...
  30. doi request reprint Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group
    Stefan Gröschel
    University Hospital Ulm, Ulm, Germany
    J Clin Oncol 31:95-103. 2013
    ..To evaluate the prognostic value of ecotropic viral integration 1 gene (EVI1) overexpression in acute myeloid leukemia (AML) with MLL gene rearrangements...
  31. pmc Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
    Bas J Wouters
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 110:3706-14. 2007
    ..A gene expression prediction signature allowed the detection of similar cases of leukemia in independent series of AML...
  32. doi request reprint High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
    Martine E D Chamuleau
    Department of Hematology, VU University Medical Centre, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Haematologica 93:1894-8. 2008
    ..Inhibition of indoleamine 2,3-dioxygenase expressed by myeloid leukemic blasts may result in breaking immune tolerance and offers new therapeutic options for patients with acute myeloid leukemia...
  33. pmc Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1
    Sanne Lugthart
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 117:234-41. 2011
    ..Our data point to a role for EVI1 in directing aberrant promoter DNA methylation patterning in EVI1 AMLs...
  34. doi request reprint A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia
    Stefan Gröschel
    Department of Hematology, Erasmus University Medical Center, Rotterdam, 3015 GE, The Netherlands Department of Internal Medicine III, Ulm University Hospital, 89081 Ulm, Germany
    Cell 157:369-81. 2014
    ..Our data show that structural rearrangements involving the chromosomal repositioning of a single enhancer can cause deregulation of two unrelated distal genes, with cancer as the outcome. ..
  35. ncbi request reprint CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression
    Joke G Boonstra
    Department of Clinical Chemistry, University Medical Center Rotterdam, Daniel den Hoed Cancer Center, The Netherlands
    Cytometry B Clin Cytom 70:136-41. 2006
    ..Increased CD38 expression by leukemic cells has been suggested as an adverse prognostic factor in B-CLL. Several approaches have been proposed to quantify its level of expression by flow cytometry...
  36. doi request reprint Genome-wide gene expression profiling, genotyping, and copy number analyses of acute myeloid leukemia using Affymetrix GeneChips
    Mathijs A Sanders
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Methods Mol Biol 1015:155-77. 2013
    ..This chapter gives instructions and recommendations for genome-wide gene expression analyses, genotyping, and copy number analyses, as performed for AML using Affymetrix GeneChips. ..
  37. ncbi request reprint Gene expression profiling in acute myeloid leukemia
    Peter J M Valk
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Curr Opin Hematol 12:76-81. 2005
    ..This review deals with the emerging promises of gene expression profiling (GEP) and the currently accumulating knowledge about the classification and the discovery of novel disease entities in clinical acute myeloid leukemia (AML)...
  38. doi request reprint The evolving molecular genetic landscape in acute myeloid leukaemia
    Mathijs A Sanders
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Curr Opin Hematol 20:79-85. 2013
    ..As a result, the molecular landscape of AML is rapidly evolving. The purpose of this review is to discuss the recent advances made in this field, with a special focus on risk stratification of AML...
  39. doi request reprint Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia
    Renee Beekman
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 119:5071-7. 2012
    ..The sequential gain of 2 CSF3R mutations implicates abnormal G-CSF signaling as a driver of leukemic transformation in this case of SCN...
  40. ncbi request reprint The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia
    Mars B van't Veer
    Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    Haematologica 91:56-63. 2006
    ..Since the determination of the IGVH mutation status is very labor-intensive, alternative prognostically relevant markers would facilitate CLL diagnostics...
  41. pmc The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia
    Karishma K Palande
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    PLoS ONE 6:e16340. 2011
    ..These findings suggest that the control of G-CSF responses by the antioxidant protein PRDX4 may be perturbed in APL...
  42. ncbi request reprint Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion
    Bert A van der Reijden
    Institute of Haematology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Br J Haematol 118:411-8. 2002
    ..We conclude that real-time PCR is a powerful method of monitoring MRD levels and quantifying the antileukaemic effect of separate (experimental) courses of chemotherapy...
  43. ncbi request reprint The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation
    Stefan J Erkeland
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 101:1111-7. 2003
    ..Collectively, these data imply a possible role of perturbed expression of YY1 in the development of AML through interference with the myeloid differentiation program in the leukemic progenitor cells...
  44. pmc Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
    Wendy Deenik
    Erasmus University Medical Center, Rotterdam, The Netherlands
    Haematologica 95:914-21. 2010
    ....
  45. ncbi request reprint Leukemic predisposition of pSca-1/Cb2 transgenic mice
    Marieke Joosten
    The Institute of Hematology, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Exp Hematol 30:142-9. 2002
    ..To determine the effect of Cb2 overexpression on hematopoietic development in vivo, Cb2 transgenic mice were generated...
  46. ncbi request reprint Gene expression profiling in acute myeloid leukemia
    Lars Bullinger
    Department of Internal Medicine III, University of Ulm, Robert Koch Str 8, D 89081 Ulm, Germany
    J Clin Oncol 23:6296-305. 2005
    ....
  47. ncbi request reprint A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML
    Bas J Wouters
    Blood 109:389-90. 2007
  48. ncbi request reprint High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients
    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
    Institute of Hematology, Erasmus Medical Centre, Rotterdam, Netherlands
    Blood 101:837-45. 2003
    ..Our data demonstrate that high EVI1 expression is an independent poor prognostic marker within the intermediate- risk karyotypic group...
  49. ncbi request reprint Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients
    Fernando P G Silva
    Department of Toxicogenetics, Leiden University Medical Center, Leiden, The Netherlands
    Haematologica 92:1123-6. 2007
    ..In conclusion, our results show that trisomy 13 is correlated to RUNX1 mutation and increased FLT3 expression in AML-M0...
  50. ncbi request reprint Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias
    Rory S Care
    Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK
    Br J Haematol 121:775-7. 2003
    ..6%) with t(8;21) AML. All mutations were mutually exclusive; 40% of inv(16) AML patients possessed either a c-KIT or FLT3 mutation. c-KIT exon 8 mutations were shown to be a significant factor adversely affecting relapse rate...
  51. doi request reprint A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)
    Arcangelo Liso
    Institute of Hematology, University of Foggia, Foggia, Italy
    Haematologica 93:1219-26. 2008
    ..This model fits with the hypothesis that NPMc(+) acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele...
  52. ncbi request reprint Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol
    Meritxell Alberich Jorda
    Institute for Hematology, Erasmus University Rotterdam, The Netherlands
    Blood 99:2786-93. 2002
    ..Our study demonstrates that a major function of Cb2 receptor expressed on myeloid leukemia cells or normal splenocytes is stimulation of migration...
  53. ncbi request reprint Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites
    Marieke Joosten
    The Institute of Hematology, Erasmus University Rotterdam, Dr Molewaterplein 50, 3015GE Rotterdam, The Netherlands
    Oncogene 21:7247-55. 2002
    ....
  54. pmc AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion
    James C Mulloy
    Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
    Proc Natl Acad Sci U S A 102:4016-21. 2005
    ....
  55. ncbi request reprint Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16)
    Peter J M Valk
    Haematologica 89:106. 2004